Section 5: Pharmacology I: Agents for arrhythmias

Circulation

Volumn 102, Issue 8 SUPPL., 2000, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DISOPYRAMIDE; DOPAMINE; FLECAINIDE; IBUTILIDE; ISOPRENALINE; LIDOCAINE; PROCAINAMIDE; PROPAFENONE; SOTALOL; VERAPAMIL;

CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG INDICATION; HEART ARRHYTHMIA; HEMODYNAMICS; HUMAN; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0034702822     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (166)

1. Peripheral vs central circulation times during CPR: A pilot study
2. Central versus peripheral intravenous routes in cardiopulmonary resuscitation
3. Lidocaine levels during CPR: Differences after peripheral venous, central venous, and intracardiac injections
4. Effect of injection site on circulation times during cardiac arrest
5. A prospective study of femoral versus subclavian vein catheterization during cardiac arrest
6. Effects of different techniques of endotracheal epinephrine administration in pediatric porcine hypoxic-hypercarbic cardiopulmonary arrest
7. Epinephrine blood concentrations after peripheral bronchial versus endotracheal administration of epinephrine in dogs
8. Endotracheal drug delivery
9. Esophageal electrocardiography: A new technology revives an old technique
10. Esophageal electrocardiography in acute cardiac care: Efficacy and diagnostic value of a new technique
11. Transesophageal electrocardiography using a temporary pacing balloon-tipped electrode in acute cardiac care
12. Transesophageal electrocardiography and adenosine in the diagnosis of wide complex tachycardia
13. Wide complex tachycardia: Misdiagnosis and outcome after emergent therapy
14. Wide QRS complex tachycardia: Reappraisal of a common clinical problem
15. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex
16. The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: Ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricular tachycardia with anterograde conduction over an accessory pathway
17. The differential diagnosis on the electrocardiogram between ventricular tachycardia and preexcited tachycardia
18. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex
19. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias
20. Misdiagnosing ventricular tachycardia in patients with underlying conduction disease and similar sinus and tachycardia morphologies
21. Ventricular tachycardia may masquerade as supraventricular tachycardia in patients with preexisting bundle-branch block
22. Evaluation of the specificity of morphological electrocardiographic criteria for the differential diagnosis of wide QRS complex tachycardia in patients with intraventricular conduction defects
23. Failure to agree on the electrocardiographic diagnosis of ventricular tachycardia
24. Diagnostic clues from the surface ECG to identify idiopathic (fascicular) ventricular tachycardia: Correlation with electrophysiologic findings
25. Lidocaine in the prevention of primary ventricular fibrillation: A double-blind, randomized study of 212 consecutive patients
26. Effects of prophylactic lidocaine in suspected acute myocardial infarction: An overview of results from the randomized, controlled trials
27. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction
28. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction
29. Prophylactic lidocaine use in acute myocardial infarction: Incidence and outcomes from two international trials
30. Lack of effectiveness of lidocaine for sustained, wide QRS complex tachycardia
31. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction
32. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia
33. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia
34. Adenosine in the diagnosis of broad complex tachycardia
35. Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia
36. Intravenous adenosine triphosphate during wide QRS complex tachycardia: Safety, therapeutic efficacy, and diagnostic utility
37. Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections
38. Life-threatening alterations in heart rate after the use of adenosine in atrial flutter
39. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide: Evidence for distinct mechanisms
40. Intermittent intravenous procaine amide to treat ventricular arrhythmias: Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure
41. Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm
42. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion
43. Facilitating influence of procainamide on conversion of atrial flutter by rapid atrial pacing
44. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing
45. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment
46. Procainamide infusion and acute atrial fibrillation
47. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion
48. The Wolff-Parkinson-White syndrome: Pharmacologic effects of procaine amide
49. Differential effect of intravenous procainamide on anterograde and retrograde accessory pathway refractoriness
50. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: Importance of atrial fibrillatory cycle length
51. Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway
52. Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome
53. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone
54. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm
55. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study
56. A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery
57. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias
58. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias
59. Ectopic automatic atrial tachycardia in children: Clinical characteristics, management and follow-up
60. Intravenous amiodarone in the acute termination of supraventricular arrhythmias
61. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: A placebo-controlled study
62. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias
63. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias
64. The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery
65. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: Amiodarone vs quinidine for conversion of atrial fibrillation
66. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation
67. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: A randomized, digoxin-controlled study
68. Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation
69. Management of atrial tachyarrhythmias in the critically ill: A comparison of intravenous procainamide and amiodarone
70. A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion
71. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction
72. Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response
73. Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients
74. Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children
75. Electrical cardioversion after amiodarone administration
76. Amiodarone prophylaxis for tachycardias after coronary artery surgery: A randomised, double blind, placebo controlled trial
77. Hemodynamic responses to amiodarone in critically ill patients receiving catecholamine infusions
78. Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient
79. Effect of intravenous amiodarone on electrophysiologic variables and on the modes of termination of atrioventricular reciprocating tachycardia in Wolff-Parkinson-White syndrome
80. The effective treatment of multifocal atrial tachycardia with amiodarone
81. Clinical efficacy and safety of intravenous amiodarone in infants and children
82. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia
83. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation
84. Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias
85. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia
86. Acute hemodynamic and antiischemic effects of intravenous amiodarone
87. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation
88. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias
89. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias
90. Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function
91. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
92. Effect of loading dose of procainamide on left ventricular performance in man
93. The antiarrhythmic properties of lidocaine and procaine amide
94. Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: A comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes
95. Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes)
96. Effects of atrial pacing, isoprenaline and lignocaine on experimental polymorphous ventricular tachycardia
97. Torsade de pointes with sotalol overdose treated successfully with lidocaine
98. Selective depression of the ischemic and hypoxic myocardium by lidocaine
99. Beneficial effect of lidocaine on ventricular electrical stability and spontaneous ventricular fibrillation during experimental myocardial infarction
100. Effect of lidocaine on the ventricular fibrillation threshold in the dog during acute ischemia and premature ventricular contractions
101. Lidocaine in cardiac resuscitation from ventricular fibrillation
102. Electrophysiological properties of canine Purkinje cells in one-day-old myocardial infarction
103. Effects of lidocaine on hypoxic and ischemic cardiac cells
104. Antifibrillatory effects of high dose bretylium and a lidocaine-bretylium combination during cardiopulmonary resuscitation
105. Lidocaine in out-of-hospital ventricular fibrillation: Does it improve survival?
106. Lidocaine in prehospital countershock refractory ventricular fibrillation
107. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: A randomized clinical trial
108. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system
109. Intravenose Amiodaron-Applikation bei therapierefraktarem Kammerflimmern
110. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation
111. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest?
112. Resuscitation from ventricular fibrillation: Drug therapy
113. The effect of lidocaine and bretylium on the defibrillation threshold during cardiac arrest and cardiopulmonary resuscitation
114. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs
115. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: Sodium channel block and action potential prolongation
116. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements
117. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: Experimental studies
118. Bretylium tosylate versus lidocaine in experimental cardiac arrest
119. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: Experimental study
120. Association of drug therapy with survival in cardiac arrest: Limited role of advanced cardiac life support drugs
121. Magnesium therapy for torsades de pointes
122. Treatment of torsade de pointes with magnesium sulfate
123. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: Safety data and recommendations for future studies
124. Randomised trial of magnesium in in-hospital cardiac arrest
125. Randomized controlled trial of Amiodarone vs Placebo in the early treatment of refractory VF arrest in the out-of-hospital setting
126. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study
127. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome
128. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia
129. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
130. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial
131. Intravenous flecainide acetate for supraventricular tachycardias
132. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia
133. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias
134. Treatment of atrial ectopic tachycardia in infants < 6 months old
135. Atrial fibrillation and flutter: Immediate control and conversion with intravenously administered verapamil
136. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter
137. Double-blind crossover randomized trial of intravenously administered verapamil: Its use for atrial fibrillation and flutter following open heart surgery
138. Role of intravenous verapamil in supraventricular tachyarrhythmias after open-heart surgery
139. Treatment of supraventricular arrhythmias with intravenous and oral verapamil
140. Verapamil in atrial fibrillation and atrial flutter
141. Supraventricular tachyarrhythmias and rate-related hypotension: Cardiovascular effects and efficacy of intravenous verapamil
142. Short-term control of supraventricular tachycardia with verapamil infusion and calcium pretreatment
143. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram
144. Esmolol: Safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias
145. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter
146. Esmolol: A new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias
147. Safety and efficacy of esmolol (ASL-8052: An ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias
148. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias
149. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias: A multicentre study
150. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter
151. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery
152. Emergency management of atrial fibrillation and flutter: Intravenous diltiazem versus intravenous digoxin
153. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias
154. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure
155. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter
156. Usefulness of diltiazem in the acute management of supraventricular tachyarrhythmias in the elderly
157. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter
158. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo
159. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure
160. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high-dose amiodarone: A randomized, placebo-controlled study
161. Effects of intravenous sotalol in patients with atrioventricular accessory pathways
162. Adenosine and supraventricular tachycardia
163. Vasoactive drugs and the importance of renal perfusion pressure
164. Low-dose dopamine in critically ill oliguric patients: The influence of the renin-angiotensin system
165. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure?
166. Acute renal failure